In this section
@article{Okell:2026,
author = {Okell, L and Courlet, P and Venezia, F and Oeuvray, C and Demarta, C and Spangenberg, T and Okebe, J},
journal = {Antimicrobial Agents and Chemotherapy},
title = {Modelling the potential effect of cabamiquine-pyronaridine for chemoprevention against Plasmodium falciparum malaria},
year = {2026}
}
TY - JOUR
AB - Preventive treatment (chemoprevention) is a key intervention for reducing the burden of Plasmodium falciparum malaria in children. The impact of the current widely-used drug combination, sulphadoxine–pyrimethamine-amodiaquine (SP-AQ), is challenged by emerging drug resistance and adherence to multi-day dosing. Cabamiquine is a novel antimalarial with activity against liver and blood stage malaria parasites, administered as a single dose and under development in combination with pyronaridine. We used mathematical modelling to translate early phase 1 clinical results into estimates of its potential impact as malaria chemoprevention. Pharmacokinetic–pharmacodynamic (PKPD) models of cabamiquine and pyronaridine were combined, assuming Bliss independence, to estimate time-varying protection against infection. PKPD results were incorporated into an established individual-based malaria transmission model to evaluate the impact of seasonal malaria chemoprevention (SMC) across settings with differing transmission and seasonality. Cabamiquine–pyronaridine was predicted to provide protection of >95% for approximately four weeks, slightly outperforming SP-AQ even in children who fully adhere to SP-AQ treatment. Six weeks after treatment, cabamiquine-pyronaridine protection dropped for the regimens containing <200mg cabamiquine, but the combination could still outperform SP-AQ at doses ≥200mg. When deployed as SMC, longer duration of protection may enable fewer, more widely spaced treatment cycles while maintaining impact, improving projected cost-effectiveness. Cabamiquine–pyronaridine shows strong potential as a next-generation single-dose chemoprevention regimen, supporting continued clinical development and evaluation.
AU - Okell,L
AU - Courlet,P
AU - Venezia,F
AU - Oeuvray,C
AU - Demarta,C
AU - Spangenberg,T
AU - Okebe,J
PY - 2026///
SN - 0066-4804
TI - Modelling the potential effect of cabamiquine-pyronaridine for chemoprevention against Plasmodium falciparum malaria
T2 - Antimicrobial Agents and Chemotherapy
ER -
For any enquiries related to the Centre please contact:
Scientific Manager
Susannah Fisher
mrc.gida@imperial.ac.uk
External Relationships and Communications Manager
Dr Sabine van Elsland
s.van-elsland@imperial.ac.uk